Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LARTRUVO vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Olaratumab is a recombinant human Ig G1 monoclonal antibody that binds to platelet-derived growth factor receptor alpha (PDGFRα), blocking PDGF-AA, -BB, and -CC binding and receptor activation, thereby inhibiting tumor growth.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery, in combination with doxorubicin.
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
10 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life is approximately 11 days (range 4–20 days), supporting a 3-week dosing interval when combined with doxorubicin.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Olaratumab is a monoclonal antibody expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways identified.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Olaratumab is cleared primarily via proteolytic catabolism; no specific renal or biliary excretion studies have been conducted. In patients, only trace amounts are excreted in urine (<1% of dose).
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Approximately 90% bound to plasma proteins (primarily Ig G, as a monoclonal antibody).
Approximately 85-90% bound to serum albumin.
Central volume of distribution is approximately 4.1 L (0.058 L/kg for a 70 kg patient), indicating limited extravascular distribution, consistent with a large monoclonal antibody.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
100% (intravenous administration only; not bioavailable orally).
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
No dose adjustment required for mild to moderate renal impairment (CLcr 30-89 m L/min). Not studied in severe renal impairment (CLcr <30 m L/min) or end-stage renal disease; use only if benefit outweighs risk.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate or severe (Child-Pugh B or C): not studied; use only if benefit outweighs risk.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Safety and efficacy not established in pediatric patients; no recommended dose.
Not established; safety and efficacy not determined in pediatric patients.
No dose adjustment based on age; monitor for adverse reactions more frequently due to higher incidence of underlying renal or hepatic impairment and comorbidities.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
WARNING: INFUSION-RELATED REACTIONS (IRRs), INCLUDING DEATH. Serious and sometimes fatal infusion-related reactions can occur. Premedicate and monitor during infusion. Interrupt or permanently discontinue based on severity.
None.
Infusion-related reactions (including severe and fatal); embryo-fetal toxicity; neutropenia; cardiotoxicity (left ventricular dysfunction); and increased adverse reactions in patients with baseline left ventricular ejection fraction (LVEF) below normal.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
None known.
Hypersensitivity to AURLUMYN or any of its components.
No specific food interactions known. However, doxorubicin may cause nausea and vomiting; advise taking antiemetics as prescribed and eating small, frequent meals. Avoid grapefruit and grapefruit juice as they may affect CYP3A4 metabolism of doxorubicin.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
Based on its mechanism of action (PDGFR-alpha inhibitor) and animal studies, LARTRUVO (olaratumab) is expected to cause fetal harm when administered to pregnant women. There are no adequate human data. In animal reproduction studies, administration of olaratumab to pregnant monkeys during organogenesis resulted in embryofetal toxicity including increased abortion and fetal anomalies. Use is contraindicated in pregnancy; advise females of reproductive potential to use effective contraception during treatment and for at least 3 months after the last dose. Risks apply throughout all trimesters.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
No data on the presence of olaratumab in human milk, effects on the breastfed infant, or milk production. Due to the potential for serious adverse reactions, advise women not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio is unknown.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
LARTRUVO is contraindicated in pregnancy. No dose adjustments during pregnancy have been studied. Pharmacokinetics may alter due to pregnancy-induced changes in volume of distribution, protein binding, and clearance; however, no specific dose adjustment guidelines exist. If treatment is absolutely necessary in a pregnant patient (which is not recommended), consider therapeutic drug monitoring if feasible.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
LARTRUVO (olaratumab) is a PDGFRα inhibitor used in combination with doxorubicin for advanced soft tissue sarcoma not amenable to surgery or radiotherapy. Monitor for infusion-related reactions and pre-medicate with antihistamines and corticosteroids. Assess cardiac function via echocardiogram or MUGA scan before each cycle due to doxorubicin cardiotoxicity. Neutropenia is common; monitor CBCs before each cycle and hold for ANC <1000/mm3. Olaratumab does not require dose adjustment for mild to moderate hepatic impairment but avoid in severe impairment. No dose adjustment for renal impairment. Pregnancy category D: advise effective contraception during and for 3 months after treatment.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
This medication is given as an intravenous infusion over 60 minutes on Day 1 and Day 8 of each 21-day cycle.,You will receive it together with another chemotherapy drug called doxorubicin.,Common side effects include nausea, fatigue, low white blood cell counts, and infusion-related reactions (fever, chills, shortness of breath).,Report any signs of infection (fever, sore throat) or unusual bleeding/bruising immediately.,Avoid pregnancy and breastfeeding while on this treatment; use effective birth control during and for 3 months after the last dose.,Do not take any other medications, supplements, or herbal products without consulting your doctor.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LARTRUVO vs AURLUMYN, answered by our medical review team.
LARTRUVO is a Antineoplastic Agent that works by Olaratumab is a recombinant human Ig G1 monoclonal antibody that binds to platelet-derived growth factor receptor alpha (PDGFRα), blocking PDGF-AA, -BB, and -CC binding and receptor activation, thereby inhibiting tumor growth.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LARTRUVO and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LARTRUVO is: 10 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LARTRUVO and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LARTRUVO is classified as Category C. Based on its mechanism of action (PDGFR-alpha inhibitor) and animal studies, LARTRUVO (olaratumab) is expected to cause fetal harm when administered to pregnant women. There are no. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.